Safety of medicines in children.

abstract：INTRODUCTION:Trabectedin gained the approval by the European Medicines Agency (EMA) in 2007 for the treatment of patients affected by soft-tissue sarcomas (STS). Its safety and activity profiles have been assessed in many clinical trials as well as in standard clinical practice for > 10 years. AREAS COVERED:This artic...

journal_title：Expert opinion on drug safety

authors： Martin-Liberal J,Judson I

更新日期：2013-11-01 00:00:00

abstract：INTRODUCTION:Cardiovascular disease remains the major contributor to morbidity and mortality in diabetes. From the need to reduce cardiovascular risk in diabetes and to ensure that such risk is not exacerbated by drug treatments, governmental regulators and drug manufacturers have focused on clinical trials evaluating ...

journal_title：Expert opinion on drug safety

authors： Younk LM,Lamos EM,Davis SN

更新日期：2016-09-01 00:00:00

abstract：:Thionamides, selective inhibitors of thyroid peroxidase-mediated iodination by tyrosine residues in thyroglobulin, have been effectively used in the treatment of hyperthyroidism. The choices for initial treatment of patients with Graves' disease differ in various countries, and many physicians around the world prefer ...

journal_title：Expert opinion on drug safety

authors： Azizi F

更新日期：2006-01-01 00:00:00

abstract：:An unprecedented interest in biomarker development has arisen from the increasing use of genomic information and high-throughput technologies in the field of drug development. Monitoring global cellular responses to perturbation due to disease, drug treatment or toxicity is achieved using molecular profiling methods s...

journal_title：Expert opinion on drug safety

authors： Bailey WJ,Ulrich R

更新日期：2004-03-01 00:00:00

abstract：:Anthracyclines are among the most active chemotherapeutic agents in cancer treatment. Although infrequent, cumulative dose-dependent cardiotoxicity is nevertheless a significant side effect of this therapy resulting in reduced cardiac reserve or even frank cardiac failure. Although used in several types of malignancy,...

journal_title：Expert opinion on drug safety

authors： Ng R,Green MD

更新日期：2007-05-01 00:00:00

abstract：INTRODUCTION:Atrial fibrillation (AF) is a cause of significant morbidity and mortality. Catheter ablation for AF (CAAF) has emerged as an effective treatment option of rhythm control for patients with symptomatic AF. However, the risk of thromboembolism and bleeding in the periprocedural period represent a worrisome c...

journal_title：Expert opinion on drug safety

authors： Briceño DF,Madan N,Romero J,Londoño A,Villablanca PA,Natale A,Di Biase L

更新日期：2017-07-01 00:00:00

abstract：INTRODUCTION:Immune checkpoint inhibitors (ICIs) have rapidly changed the treatment landscape, demonstrating dramatic clinical efficacy in various cancers. AREAS COVERED:In urothelial cancer (UC), several ICIs have been approved in platinum refractory disease and also as first-line therapy in patients that fulfill the...

journal_title：Expert opinion on drug safety

authors： Economopoulou P,Kotsantis I,Bamias A

更新日期：2020-08-01 00:00:00

abstract：INTRODUCTION:Unfractionated heparin is an anticoagulant used in the treatment of myocardial infarction, pulmonary embolism and other thrombotic disorders. However, with anticoagulation comes the risk of bleeding and adverse events. These risks increase with supratherapeutic dosing. AREAS COVERED:In this review, we dis...

journal_title：Expert opinion on drug safety

authors： Krishnaswamy A,Lincoff AM,Cannon CP

更新日期：2011-01-01 00:00:00

abstract：INTRODUCTION:Gestational diabetes mellitus (GDM), the most frequent medical complication of pregnancy, is associated with several adverse outcomes over the short- and long-term for both mother and offspring. Standard treatment for GDM consists of insulin injections. Oral hypoglycemic agents (OHAs), on the other hand, a...

journal_title：Expert opinion on drug safety

authors： Maymone AC,Baillargeon JP,Ménard J,Ardilouze JL

更新日期：2011-03-01 00:00:00

abstract：BACKGROUND:The abuse and diversion of pharmacological agents with CNS mechanisms of action is an important concern from governmental, regulatory, public health and safety perspectives. In recent years, there have been an increased number of reports concerning the abuse and diversion of quetiapine in forensic population...

journal_title：Expert opinion on drug safety

authors： Tcheremissine OV

更新日期：2008-11-01 00:00:00

abstract：INTRODUCTION:Conventional systemic therapies for psoriasis are associated with serious toxicities that can limit long-term use. In recent years, biological therapies have offered the possibility of long-term therapy with improved safety and efficacy for the treatment of psoriasis. Biological therapies can be classified...

journal_title：Expert opinion on drug safety

authors： Talamonti M,Spallone G,Di Stefani A,Costanzo A,Chimenti S

更新日期：2011-03-01 00:00:00

abstract：INTRODUCTION:Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is a novel solvent-free formulation of paclitaxel, which was developed to avoid toxicities associated with Cremophor EL® vehicle used in solvent-based paclitaxel. It is approved as monotherapy for treatment of metastatic breast cancer (MBC) in Europe a...

journal_title：Expert opinion on drug safety

authors： Cecco S,Aliberti M,Baldo P,Giacomin E,Leone R

更新日期：2014-04-01 00:00:00

abstract：OBJECTIVE:Higher vancomycin concentrations are thought necessary for treatment of deep-seated methicillin-resistant Staphylococcus aureus (MRSA) infection, yet this may result in greater risk of nephrotoxicity. We evaluated the relationship of serum vancomycin trough concentration with clinical outcomes and nephrotoxic...

journal_title：Expert opinion on drug safety

authors： Hermsen ED,Hanson M,Sankaranarayanan J,Stoner JA,Florescu MC,Rupp ME

更新日期：2010-01-01 00:00:00

abstract：:Introduction: Treatment for chronic pruritus ranges from use of topical formulations to newer biologic agents. Targeting treatment to the underlying etiology is key in reducing the burden of disease while avoiding systemic or adverse effects.Areas covered: This review details the effective medical treatments used in v...

journal_title：Expert opinion on drug safety

authors： Fourzali K,Yosipovitch G

更新日期：2020-04-01 00:00:00

abstract：:Introduction: Rucaparib is increasingly being utilized for women with recurrent ovarian cancer both as treatment and maintenance therapy. Poly-ADP ribose polymerase (PARP) inhibitors like rucaparib are daily oral medication that exploit the DNA repair pathway. The most significant clinical benefit is in those tumors e...

journal_title：Expert opinion on drug safety

authors： Cosgrove CM,O'Malley DM

更新日期：2018-12-01 00:00:00

abstract：INTRODUCTION:Cardiac injury is one of the most impairing side effects of anticancer treatment. The extension of the range of available drugs, the use of combination regimens and the association with radiation therapy have improved life expectancy; however, they have also caused a rising typology of cardiac toxicities, ...

journal_title：Expert opinion on drug safety

authors： Minoia C,Giannoccaro M,Iacobazzi A,Santini D,Silvestris N,Fioretti A,Oliva S,Guarini A

更新日期：2012-09-01 00:00:00

abstract：IMPORTANCE OF THE FIELD:Despite the beneficial effect of imatinib treatment in chronic myeloid leukemia patients, some patients develop resistance and/or intolerance and need a switch to second-generation tyrosine kinase inhibitors. Dasatinib is indicated for chronic myeloid leukemia patients with resistance or intoler...

journal_title：Expert opinion on drug safety

authors： Breccia M,Alimena G

更新日期：2010-09-01 00:00:00

abstract：:Objectives: This study aimed to develop a procedure to explore the adverse drug reaction signals of drug-induced neutropenia (DIN) or drug-induced agranulocytosis (DIA) in children using an electronic health records (EHRs) database. Methods: A two-stage design was presented. First, the suspected drugs to induce DIN or...

journal_title：Expert opinion on drug safety

authors： Wei R,Jia LL,Yu YC,Nie XL,Song ZY,Fan DF,Xie YF,Peng XX,Zhao ZG,Wang XL

更新日期：2019-05-01 00:00:00

abstract：INTRODUCTION:In 1998, high-dose interleukin-2 (IL-2) was the first immunotherapy approved for the treatment of metastatic melanoma based on durable objective responses documented in a subset of patients but widespread utilization was limited by significant toxicity. Advances in targeted therapy and the emergence of T c...

journal_title：Expert opinion on drug safety

authors： Marabondo S,Kaufman HL

更新日期：2017-12-01 00:00:00

abstract：:Most regulatory agencies and pharmaceutical companies focus the majority of their pharmacovigilance on safety signal identification in large databases. GlaxoSmithKline (GSK) has > 100 drugs marketed worldwide. In order to determine which database has the highest statistical power to detect safety signals in three larg...

journal_title：Expert opinion on drug safety

authors： Hammond IW,Gibbs TG,Seifert HA,Rich DS

更新日期：2007-11-01 00:00:00

abstract：INTRODUCTION:Sulfasalazine (SASP) is a drug commonly used in the treatment of inflammatory bowel diseases (IBD) such as ulcerative colitis and Crohn's disease (CD) and rheumatoid arthritis (RA). A high incidence of side effects limits therapy with this drug. Getting a wider knowledge of drug pharmacology, indications a...

journal_title：Expert opinion on drug safety

authors： Linares V,Alonso V,Domingo JL

更新日期：2011-03-01 00:00:00

abstract：OBJECTIVE:Further understand the safety profile of celecoxib and provide safety information for important adverse events (AEs). METHODS:Analysis of randomized controlled trials from the Pfizer clinical trial repository (final study reports completed by 31 July 2011) in which celecoxib was compared with placebo or non-...

journal_title：Expert opinion on drug safety

authors： Essex MN,Zhang RY,Berger MF,Upadhyay S,Park PW

更新日期：2013-07-01 00:00:00

abstract：INTRODUCTION:Basiliximab is a chimeric monoclonal antibody directed against the alpha chain of interleukin-2 receptor (IL-2R). When administered intravenously at a dosage of 20 mg at the time of transplantation and 4 days later, basiliximab saturates the alpha chain of IL-2R for 4 weeks. AREAS COVERED:This review eval...

journal_title：Expert opinion on drug safety

authors： Ponticelli C

更新日期：2014-03-01 00:00:00

abstract：INTRODUCTION:Albiglutide is a marketed long acting GLP-1 receptor agonist (GLP-1 RA) administered by weekly injection. It has significantly less gastrointestinal side effects than other GLP-1 RAs in current use but does not improve HbA1c or promote weight loss to the same extent as competitor agents such as liraglutide...

journal_title：Expert opinion on drug safety

authors： Rendell MS

更新日期：2017-09-01 00:00:00

abstract：INTRODUCTION:Carbonic anhydrase (CA) inhibitors have an impressive safety record despite the multiple functions that CA isozymes serve because they are not fully inhibited with most dosing. While reducing the targeted CA-dependent process sufficiently for disease control, residual activity and uncatalyzed rates in comb...

journal_title：Expert opinion on drug safety

authors： Swenson ER

更新日期：2014-04-01 00:00:00

abstract：INTRODUCTION:Obesity is associated with an increased risk of cardiovascular morbidity and mortality. Four medications are approved by the US Food and Drug Administration (FDA) for chronic weight management when used as an adjunct to a reduced-calorie diet and increased physical activity in adults. These medications res...

journal_title：Expert opinion on drug safety

authors： Chao AM,Wadden TA,Berkowitz RI,Quigley K,Silvestry F

更新日期：2020-09-01 00:00:00

abstract：:The widespread application of protocols using gonadotropin-releasing hormone (GnRH) agonists or antagonists in assisted reproduction treatment has led to an increasing number of pregnancies exposed to these drugs. This issue has raised scepticism as to the safety of these medications, concerning both pregnant women an...

journal_title：Expert opinion on drug safety

authors： Tarlatzis BC,Bili H

更新日期：2004-01-01 00:00:00

abstract：:NSAIDs are used extensively worldwide at a cost of billions of dollars annu-ally. Adverse side effects, especially in the gastrointestinal (GI) tract, are uncommon but cause a substantial burden of illness because of the volume of use. Important upper GI complications include dyspepsia, gastric erosions and peptic ulc...

journal_title：Expert opinion on drug safety

authors： Peng S,Duggan A

更新日期：2005-03-01 00:00:00

abstract：INTRODUCTION:Hydroxychloroquine (HCQ) is an alkalinizing lysosomatropic drug that accumulates in lysosomes where it inhibits some important functions by increasing the pH. HCQ has proved to be effective in a number of autoimmune diseases including systemic lupus erythematosus (SLE). Areas covered: In this review the me...

journal_title：Expert opinion on drug safety

authors： Ponticelli C,Moroni G

更新日期：2017-03-01 00:00:00

abstract：INTRODUCTION:There is now 16 years' worth of established results of various trials demonstrating the bortezomib efficiency in the treatment of multiple myeloma. Over this time, the introduction of bortezomib has been a major break through in the treatment of multiple myeloma. Bortezomib can be administered in the outpa...

journal_title：Expert opinion on drug safety

authors： Cengiz Seval G,Beksac M

更新日期：2018-09-01 00:00:00